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Accepted 1 June 2014; Published online 10 September 2014AbstractObjectives: New evidence continues to emerge and requires attention after the release of a clinical practice guideline (CPG). The
objective of this article is to describe the Document Assessment and Review (DAR) strategy designed to ensue that the CPGs remain current
and their quality maintained and to present the results of two iteration of its implementation.
Study Design and Setting: The DAR process involves an annual assessment of our CPGs and a review of documents that require an
update search. Two questionnaires are used to conduct the annual assessment and the review. The review involves evidence search, evidence
review, and review approval.
Results: In 2011, 109 documents were assessed; 22 (20%) were archived, 1 (1%) was deferred for assessment in 2012, 24 (22%) were
considered special cases and 62 (57%) needed a new systematic review of the evidence. Of those 62, 19 (31%) were categorized as urgent,
16 (26%) as high, and others as medium or low priority. In 2012, 88 total documents were assessed; 15 (17%) were archived, 32 (36%)
deferred, 3 (3%) were considered special cases, and 38 (43%) were prioritized for review.
Conclusions: Assessment and prioritization of existing CPGs are effective ways of ensuring that resources are directed toward the up-
keep of those that are relevant and of highest priority.  2014 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. Introduction and in some clinical fields, they have been used to signalEvidence-based CPGs are systematically developed
statements based on research evidence that serve as a useful
guide for patients, health care practitioners, and policy
makers. Their intent is to optimize patient care by identi-
fying the most effective care options and through the
harmonization of clinical decision making [1e3]. Their
quality and usefulness have been positively correlated with
the productivity of the producer [3e7]. In many regions,
they form the basis for health policy around funding prior-
ities and access to care and health care system organization,Conflict of interest: The authors declare that they do not have any poten-
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Despite their usefulness, their lifespan is limited because of
the rapidly changing and evolving nature of clinical evidence
on which recommendations are based. New evidence con-
tinues to emerge after their production, and the recommenda-
tions may become compromised when they are no longer
reflective of current clinical literature [4,5]. This may lead to
incorrect or less-optimal actions if used inadvertently by clini-
cians, patients, and government or organizational decision
makers. Survival analysis conducted by Shekelle et al. [12]
showed that most CPGs remain valid for a period of 3.6 years.
Regular monitoring of existing CPGs and timely dissemi-
nation of updated ones are essential ways of ensuring that
CPGs remain useful in improving health care quality and
patient outcome [1,5e7,13e20]. Indeed, CPG updating is
an essential component of high-quality CPGs [21e24], but
there is limited evidence on the ideal strategy for monitoring
and updating them [25], and most of the CPG-developingess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 A clinical practice guideline (CPG)eupdating proce-
dure requires rigor yet a pragmatic efficiency to make
it viable for implementation. Prioritizing the review
of CPGs help to ensure that resources are directed
to documents that are relevant and of high priority.
What this adds to what was known?
 Updating CPGs is an essential component of high-
quality CPGs. As new evidence emerges, it is
important that CPGs are regularly updated. A
CPG-updating procedure requires rigor yet a prag-
matic efficiency to make it viable for implementa-
tion. This article presents a systematic approach of
reviewing and updating CPGs to ensure that they
remain current and useful in improving health care
quality and patient outcome.
What is the implication and what should change
now?
 Regular monitoring of existing CPGs and timely
dissemination of updated ones are essential ways of
ensuring thatCPGs remainuseful in improvinghealth
care quality and patient outcome. However, there is
limited evidence on the ideal strategy for monitoring
and updating them because most CPG-developing
groups do not have a formal update procedure in
place. The procedure described in this article, if adop-
ted by other developers, would help in improving and
standardizing the way CPGs are updated.
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[15,16]. Updating a CPG can be as costly and time
consuming as developing a new one. Even when procedures
do exist, high-volume guideline developers may have diffi-
culty keeping all of their guidelines up to date, as maintain-
ing an old document may not be as high a priority as
creating a new one.
Thus, a CPG-updating procedure requires rigor yet a prag-
matic efficiency to make it viable for implementation. The
purpose of this article was to describe and provide the results
of the first 2 years of implementation of a new CPG-updating
procedure, theDocumentAssessment andReview (DAR) pro-
cess that was used to ensure that cancer CPGs remain current.
2. Methods
2.1. Study context
The DAR process was developed by a research team of
the Program in Evidence-based Care (PEBC). The PEBC isthe CPG initiative of the Ontario provincial cancer system,
Cancer Care Ontario (CCO), supported by the Ontario Min-
istry of Health and Long Term Care, and academically
linked to McMaster University, Canada. The PEBC
mandate is to improve the quality of cancer care and the
lives of Ontarians affected by cancer, through the develop-
ment, dissemination, and evaluation of evidence-based
CPGs and other advice documents that are designed to
facilitate clinical, planning, and policy decisions about can-
cer control. The PEBC follows the guideline development
cycle to produce a CPG [26,27]. Most PEBC documents
use a common structural template composed of (1) the
CPG recommendations, (2) evidentiary base, and (3) the
development and external review methods.2.2. DAR protocol
In 2011, the PEBC designed the DAR protocol building
off previous updating procedures of the PEBC and strate-
gies used by other noted CPG developers such as Scottish
Intercollegiate Guidelines Network and National Institute
for Health and Care Excellence [28,29]. The DAR process
comprised two stepsdthe document assessment step and
the document review step [30].2.3. Step 1: document assessment
The purpose of the assessment was to identify CPGs that
are no longer applicable to current practice and documents
with recommendations that may have been, have the poten-
tial to be, or are expected to be invalidated by new evidence.
In consultation with a clinical expert, the assessment of
PEBC CPGs is facilitated annually by a methodologist using
the document assessment questionnaire (DAQ). The DAQ
consist of six questions assessing the following: (1) the cur-
rent relevance of the CPG to cancer care, (2) the timing of
the assessment, (3) the need for updated literature search
and the appropriateness of the questions and search criteria,
(4) the impact of the CPG on access to care, (5) the avail-
ability of new evidence capable of invalidating the existing
recommendations, and (6) the risk of leaving the document
publicly available while undergoing DAR (see Appendix A
at www.jclinepi.com).
The application of the DAQ classifies each candidate
CPG into one of the following four groups: (1) endorse,
(2) defer, (3) review, or (4) archive the CPG document.
Endorsement means that the recommendations are still cur-
rent and relevant for decision making. This can happen
when there is a very strong justification to conclude that
without a search for new evidence, the recommendations
are still valid, for example, in cases in which added evidence
will not change the recommendations because the existing
evidence is so definitive, of high quality, and adequate quan-
tity or in cases in which no additional evidence in that topic
will be forthcoming because it is no longer an area of in-
quiry. Defer means that the document remains current and
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means that the document will undergo a review for currency
and relevance. Archive means that the document cannot be
endorsed or deferred, and the recommendations will no
longer be maintained. This may happen because the recom-
mendations are no longer clinically relevant and applicable
to current practice. Or, it may be because the developing
group has little or no interest in maintaining them; for
example, the topic areas may have changed so much that
developing a new document is a more practical option than
updating the existing one. Archived documents may still be
useful for academic or other information purposes, but
PEBC does not assign resources toward maintaining an
archived document. Documents that do not fall into any of
these four outcome categories are considered special cases.
The special case documents are still relevant, but for some
reasons (eg, the group that originally produced it no longer
exists), they are not suitable for a traditional review and they
cannot be deferred or archived.
For the CPGs that fall within the review category, an
intermediary step of topic prioritization using the criteria
set out in Fig. 1 is used to determine the priority of review.
Prioritized guidelines are considered relevant; their ques-
tions and search criteria are still applicable to current needs
and practices. Urgent priority is given to any document
known to be instrumental in deciding who gets funding
or access to care in Ontario and low priority to documents
presumed to have no new evidence. All prioritized docu-
ments move to step two of our process.2.4. Step 2: document review
Documents categorized as review from step 1 are
eligible for step 2. The purpose of the document review
process was to ensure that any evidence published since
the CPG was completed or last reviewed is considered. In
order of their priority determined in the previous step, a
clinical expert and a methodologist review the eligible
guidelines using the document review questionnaire
(DRQ). The DRQ has four questions that help the clinical
expert determine the effect of the new evidence on the ex-
isting recommendation and the actions that will be taken
(see Appendix B at www.jclinepi.com).
For each document, the methodologist conducts a
streamlined systematic review of new evidence using the
original search strategy and study selection criteria. Study
characteristics and new evidence from the studies, system-
atic reviews, and meta-analyses identified through a
comprehensive search of electronic databases are extracted
and summarized by the methodologist. In contrast to a
traditional systematic review, the streamline review is
completed without conducting a full quality assessment.
The clinical expert reviews the new evidence to determine
(1) if it supports or contradicts current recommendations;
(2) if the current recommendations cover all relevant sub-
jects addressed by the new evidence, and (3) if strongevidence that may change the current recommendations is
expected to be published in the near future. Based on the
clinical expert’s responses to the DRQ questions, each
document is assigned one of the following outcomes also
used in step 1: endorse, update, or archive. Endorse means
that the newly identified evidence supports the current rec-
ommendations with only minor changes or new qualifying
statements; update means that the new evidence requires
changes to the existing recommendations, and the PEBC
and the DSG/GDG are able to commit resources to
rewriting the document in the next year; and archive means
that the document cannot be endorsed or deferred, and a
full update is not either feasible or desired.
The clinical content of the guideline and the outcomes of
the update process are reviewed and approved by a larger
expert panel comprising a multidisciplinary team of clini-
cians and other stakeholders. The updating process is
communicated in a specific section of the CPG that summa-
rizes the DAR process, and the results of the review and the
history of the document are added to the original document.
A 75% quorum of the panel membership is required, and
75% of the quorum has to approve the document.
2.5. Communicating the status to our users
PEBC CPGs are made publicly available to our user on
the CCO’s Web site. The Web site is frequently updated to
reflect the status of each document. The three possible sta-
tus categories for our documents are labeled on the Web
site: current, archived, and in review. Current documents
are documents that are considered trustworthy by the PEBC
and are still being maintained. Archived documents are
documents that are no longer maintained by the PEBC.
They are watermarked and moved to a separate section of
the CCO Web site designated for academic or other infor-
mational purposes. In-review documents are documents
that are undergoing further consideration by the PEBC.
The pages of in-review documents are also watermarked,
and after the completion of the assessment phase, the cover
page of every assessed document is changed to reflect the
date of assessment and the meaning of the assessment
outcome. The CURRENT or IN-REVIEW labels are boldly
written beneath the title on CCO Web site.
In the event that a CPG is identified as harmful if used
inadvertently, it is removed from the Web site, and our
users are notified to contact PEBC if they need any of these
documents.3. Results
The application of this methodology was conducted in
2011 by a team of methodologists and clinical leaders of
each guideline-developing group. Two annual assessments
and review cycles have been completed, as summarized in
Fig. 2. In 2012, the second iteration of document assessment
was completed. All results are current as of September 10,
Fig. 1. Program in Evidence-based Care assessment tool outcomes and review prioritization scheme.
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through the process. Most of the documents less than
3-years old are deferred, but rarely would a document get
an endorsement through the assessment process.3.1. Cycle 1 (September 2011 to September 2012)
During the first cycle, 109 documents older than 3 years
were assessed using the document assessment tool. Of
these, 22 (20%) were archived with no further action taken,
1 (1%) was deferred for assessment in 2012, 24 (22%) were
considered special cases in which the correct course of ac-
tion was unclear, and 62 (57%) were determined to need anew systematic review of the evidence. Of those 62, 19
(31%) were categorized as urgent priority, 16 (26%) were
categorized as high priority, and the remainder as medium
or low priority. None of the medium- or low-priority docu-
ments had a review initiated by the time of the 2012
assessment.
Of the 35 urgent- and high-priority documents from the
2011 assessment, 33 (94%) have had reviews initiated.
Twenty-two (63%) of those were initiated within 1 year.
Two high-priority documents from the 2011 assessment
have not had reviews initiated. In hindsight, these may have
been better categorized as special cases giving the nature of
the recommendations and the authoring group.
Fig. 2. Document assessment and review flow diagram.
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as a consequence of the 2011 assessment, 29 (88%) have
been completed. Of these 15 (52%) resulted in an
endorsement, eight (28%) required rewriting to correct
or update the recommendations, and six (21%) were
archived with no further action. In the case of the
archived documents, the new literature search revealed
such a wide breadth of evidence that a simple update
and/or rewrite would not be possible or identified evi-
dence that led to the conclusion that new research ques-
tions were needed or the scope of the document should
be expanded. Thus, a completely new CPG projects will
be initiated. Of the eight documents that needed rewriting
and/or updating, that work was started for only one docu-
ment. There have been insufficient staff resources to start
the remainder.Of the 24 documents considered special cases in the
2011 assessment, one had a new version initiated, two were
archived, and the remaining twenty-one were not resolved
by the beginning of the 2012 assessment.3.2. Cycle 2 (September 2012 to September 2013)
For the 2012 assessment and review cycle, 88 total doc-
uments were assessed. Of these, 42 (48%) were documents
that were at least 1 year old on September 1, 2012 and had
not previously been assessed, and the remainder were doc-
uments that had been assessed in 2011, but for various rea-
sons, no final determination had been possible (Table 1).
Of those 88 documents, 15 (17%) were archived with no
further action taken, 32 (36%) were deferred for assessment
in 2013, 3 (3%) were considered special cases, and 38 (43%)
Table 1. Change in assessment result from 2011 to 2012
2012
2011
Low Medium Special case
Low 10 2 2
Medium 5 2 3
Special case 2 d 1
Urgent d d 3
Archive 2 2 12
Total 2011 assessed in 2012 19 6 21
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have been archived, and one is pending a resolution. Of the
38 documents prioritized for review, eight (21%) were of ur-
gent priority, two (5%) were of high priority, and the
remainder were of medium or low priority. Of the 10 urgent-
and high-priority reviews, seven have been initiated.
As noted above, 46 documents that had been assessed in
2011were reassessed in 2012 as nowork had yet commenced.
Thechanges in classification after the second2012 assessment
are noted in Table 1. Of note, a majority (10 of 19, 53%) of
documents prioritized as low in 2011 were again prioritized
as low in 2012, and a majority (12 of 21, 57%) of documents
that were special cases in 2011 were archived in 2012.
3.3. Human resource requirements
During this time, roughly two full-time equivalent meth-
odologistswere responsible for implementing the assessment
and review process, although only one full-time employee
(FTE) was consistently the same person throughout the
period. The other FTE consisted of multiple staff members
devoting part of their time to conducting reviews.
3.4. Other time interval measures
Given that at the time of the 2011 assessment, therewere a
number of reviews of older documents already ongoing; it is
not yet possible to derive a reliable estimate for future plan-
ning or for use by other guideline developers of the overall
time it has taken for each document to complete the assess-
ment and review cycle. However, it is possible, given the data
that have been collected to estimate the time it has taken for
urgent- and high-priority documents, once a review has been
initiated, for a review outcome (endorsement, archive, and
update) to be approved by the expert panel.
Using KaplaneMeier methods and treating documents
not yet approved by an expert panel as censored on
September 10, 2013, the median time from the initiation
of the search to approval by the expert panel has been
167 days (range of uncensored times, 18e358 days). For
documents assigned an urgent priority, the median time
was 182 days and for high priority it was 151 days.4. Discussion
Maintaining the quality of guidelines should be a priority
for any guideline-developing group such as the PEBC. Fromour experience, the document assessment and review process
have beenvery useful in identifying CPGs that may no longer
be clinically relevant, incorporating new evidence into exist-
ing CPGs, and ensuring that our users are informed about the
current status of our documents. The process helps to direct
resources to the priority documents that really need to be up-
dated and prevents duplication of efforts by delaying an up-
date when new evidence is anticipated. The option to
endorse a document has been valuable as it significantly re-
duces the effort and time used to produce a new guideline.
In 2011, the ‘‘special case’’ category was poorly defined
and easily became the status of many documents. In 2012,
the criteria became more stringent, and the assessment was
much cleaner. We have encountered some major and minor
challenges at every step of the process.
The first major challenge we face is that even with a
stratified approach, the volume of documents requiring re-
views exceeds the availability of research methodologists
and clinical experts to commit to completing the review.
Indeed, variability in access to clinical experts explains in
part the paradoxical finding that the urgent-priority docu-
ments take longer than those classified as high-priority
ones. Also as a consequence of this, lower-priority docu-
ments have not been reviewed since the implementation
of the DAR protocol and will not likely be reviewed
without infusion of new dollars specifically geared to this.
In the absence of more resources, ‘‘low priority’’ may
become a euphemism for ‘‘archived next year.’’
Another major challenge is that we do not get the review
component completed in a timely fashion because of diffi-
culty in getting a 75% final approval from 75% of the expert
panel.We believe this to be because of the exceptionally busy
members of the expert panel and not their belief that a CPG is
not appropriate for approval; this is being explored. In
response, an alternative strategy may be required, for
example, a smaller approval body appointed to make the de-
cisions on behalf of the group. There have also been some in-
stances where panel members are equally split in reaching a
consensus. In such instances, a negotiated solution with
members of the scientific team is sought. Despite delays in
getting their input, over 200 clinicians involved in the PEBC
CPG panels have been motivated participants in the process.
They have been providing feedback in refining processes,
creating efficiencies, and this will continue.
Although the process helps to identify documents that
require a rewrite, rewriting them has also proven very task-
ing on our resources because of new CPG topics that are in
progress. If the outcome of a review is to update a docu-
ment and the update is not started by the next annual assess-
ment, the document becomes archived. Without an obvious
path to update a guideline within a year, the ‘‘update’’ cate-
gory has not been very useful in this process. PEBC is
considering the elimination of the update category in the
future as a potential response to this situation.
The major benefit of the streamlined systematic review
approach is the identification of potential evidence that
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systematic review methods, our streamlined approach fore-
goes quality appraisal of the new relevant research. The risks
of skipping this step and the potential for bias are not well un-
derstood. Nor do we have information if this efficiency mea-
sures a better approach to alternatives such as considering
only randomized controlled trial evidence in the updating pro-
cess. Continued investigations are ongoing. However, to date,
the preponderance of the new evidence we have found aligns
with existing evidence in the original guideline.
At the beginning, it was not easy communicating the re-
sults of the review to our users, but this has improved since
we decided to add a new section to the CPG document that
briefly describes its history. The speed with which elec-
tronic communication was made via the Web site was
initially slow, but improvements have been made to help
address these delays. It still takes a long time (median
167 days) to complete a DAR, but considering that two
FTE have been able to bring 29 CPGs to completion does
show an increase in efficiency over typical updating of a
guideline where an FTE could complete perhaps two
documents from search to approval in about the same
amount of time.
The DAR process was designed and implemented in the
context of an organized cancer CPG initiative. Although we
have insufficient data to make meaningful comparisons be-
tween thismethod andour previous attempts tomanageour up-
dating agenda,we know that the current strategyhas beenmore
productive, more systematic, and more transparent. Further-
more, although the principles of updating challenges are uni-
versal, it would be important for other groups to test the
universality of the procedures we have created here to deter-
mine steps that are generalizable and potential efficiencies that
can bemade in the process.There is value in theguideline com-
munity working together to document update strategies and to
work with a common set of quality indicators such as quality,
rigor and efficiency, and resources required.
We understand that rigor is often recommended over
pragmatism, but in the bid to refine our process, it is impor-
tant that we balance rigor with pragmatism remembering
that every additional step put in place requires time and hu-
man resource. Further work is required to evaluate user per-
ceptions as this will further condense the time frame by
focusing on the things that are important to the users. We
need to make choices that would make meaningful impact
to patients and health systems because they are the ultimate
recipients of the actions taken or lack of action in response
to recommendations. Validation of the two questionnaires
used in conducting the document assessment and review
will also be worthwhile to.5. Conclusion
The DAR protocol has enabled the PEBC to maintain
the currency of CPGs that are relevant to practice, to iden-
tify CPGs that may contain misleading recommendations,and to prioritize documents that require updated evidence
review. It also provides an effective way of ensuring that re-
sources are channeled toward the upkeep of those that are
relevant and of highest priority. Timely dissemination of re-
viewed CPGs has also helped to prevent inadvertent use of
outdated ones.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2014.06.013.References
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